Reta is an investigational peptide-based medication designed to target multiple hormone receptors involved in metabolism and appetite regulation. It is often described as a “triple agonist” because it activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. By stimulating these pathways simultaneously, Reta has been studied for its potential to significantly reduce appetite, improve insulin sensitivity, regulate blood sugar levels, and increase energy expenditure. In clinical research, it has demonstrated substantial weight loss effects, likely due to its combined impact on reducing caloric intake and enhancing metabolic activity.
Reta is an investigational peptide-based medication designed to target multiple hormone receptors involved in metabolism and appetite regulation. It is often described as a “triple agonist” because it activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. By stimulating these pathways simultaneously, Reta has been studied for its potential to significantly reduce appetite, improve insulin sensitivity, regulate blood sugar levels, and increase energy expenditure. In clinical research, it has demonstrated substantial weight loss effects, likely due to its combined impact on reducing caloric intake and enhancing metabolic activity.
Image 1 of 1